Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Angela Calabrese
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, Angela Calabrese wrote the following 4 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Multimodal treatment of resectable pancreatic ductal adenocarcinoma. 2017

Silvestris, Nicola / Brunetti, Oronzo / Vasile, Enrico / Cellini, Francesco / Cataldo, Ivana / Pusceddu, Valeria / Cattaneo, Monica / Partelli, Stefano / Scartozzi, Mario / Aprile, Giuseppe / Casadei Gardini, Andrea / Morganti, Alessio Giuseppe / Valentini, Vincenzo / Scarpa, Aldo / Falconi, Massimo / Calabrese, Angela / Lorusso, Vito / Reni, Michele / Cascinu, Stefano. ·Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy. Electronic address: n.silvestris@oncologico.bari.it. · Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy. Electronic address: dr.oronzo.brunetti@tiscali.it. · Department of Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Electronic address: e.vasile@ao.pisa.toscana.it. · Radiation Oncology Department, Gemelli ART, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: francesco.cellini@uniroma3.it. · ARC-NET Research Centre, University of Verona, Verona, Italy. Electronic address: cataldo.ivana@gmail.com. · Medical Oncology Unit, University of Cagliari, Cagliari, Italy. Electronic address: oncologiamedica2reparto@gmail.com. · Department of Medical Oncology, University and General Hospital, Udine, Italy. Electronic address: aprile83@gmail.com. · Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, 'Vita-Salute' University, Milan, Italy. Electronic address: partelli.stefano@hsr.it. · Medical Oncology Unit, University of Cagliari, Cagliari, Italy. Electronic address: marioscartozzi@gmail.com. · Department of Medical Oncology, University and General Hospital, Udine, Italy; Department of Medical Oncology, General Hospital of Vicenza, Vicenza, Italy. Electronic address: aprile.giuseppe@aoud.sanita.fvg.it. · Medical Oncology Unit, IRCCS, Meldola, Italy. Electronic address: casadeigardini@gmail.com. · Radiation Oncology Center, Dept. of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Italy. Electronic address: alessio.morganti2@unibo.it. · Radiation Oncology Department, Gemelli ART, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: vincenzo.valentini@unicatt.it. · ARC-NET Research Centre, University of Verona, Verona, Italy. Electronic address: aldo.scarpa@univr.it. · Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, 'Vita-Salute' University, Milan, Italy. Electronic address: falconi.massimo@hsr.it. · Radiology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy. Electronic address: acalabrese22@gmail.com. · Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy. Electronic address: vito.lorusso@oncologico.bari.it. · Medical Oncology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: reni.michele@hsr.it. · Modena Cancer Center, Policlinico di Modena Università di Modena e Reggio Emilia, Italy. Electronic address: cascinu@yahoo.com. ·Crit Rev Oncol Hematol · Pubmed #28259290.

ABSTRACT: After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

2 Article CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. 2019

Porcelli, Letizia / Iacobazzi, Rosa Maria / Di Fonte, Roberta / Serratì, Simona / Intini, Angelica / Solimando, Antonio Giovanni / Brunetti, Oronzo / Calabrese, Angela / Leonetti, Francesco / Azzariti, Amalia / Silvestris, Nicola. ·Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. porcelli.letizia@gmail.com. · Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. rosamaria.iacobazzi@gmail.com. · Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. difonte.roberta@gmail.com. · Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. simonaserrati@hotmail.com. · Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. angelicaintini@gmail.com. · Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine 'G. Baccelli', University of Bari Medical School Bari, 70124 Bari, Italy. antoniogiovannisolimando@gmail.com. · Medical Oncology Unit, Ospedale Mons. R. Dimiccoli, 76121 Barletta (Bat), Italy. dr.oronzo.brunetti1983@gmail.com. · Radiology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. acalabrese22@gmail.com. · Dipartimento di Farmacia-Scienze del Farmaco, University of Bari, 70125 Bari, Italy. francesco.leonetti@uniba.it. · Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. a.azzariti@oncologico.bari.it. · Medical Oncology Unit and Scientific Direction, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. n.silvestris@oncologico.bari.it. ·Cancers (Basel) · Pubmed #30866547.

ABSTRACT: Tumor⁻stroma interactions are of key importance for pancreatic ductal adenocarcinoma (PDAC) progression. Our aim was to investigate whether cancer associated fibroblasts (CAFs) and mast cells (MC) affected the sensitivity of PDAC cells to gemcitabine/nabpaclitaxel (GEM/NAB). For this purpose, the combination cytotoxicity and the effect on tumor invasion and angiogenesis were evaluated with or without a conditioned medium from the mast cell line HMC-1 (human mast cell line-1 cells) and CAFs. Beside the clinical outcome of a homogenous population of PDAC patients, receiving GEM/NAB, was correlated to the circulating levels of mast cell tryptase and to a panel of inflammatory and immunosuppressive cytokines. CAFs neither affected drugs' cytotoxicity nor the inhibition of angiogenesis, but promoted tumor cell invasion. The MC instead, caused resistance to drugs by reducing apoptosis, by activating the TGF-β signalling and by promoting tumor invasion. Indeed, the inhibition of TβRI serine/threonine kinase activity by galunisertib restored drugs cytotoxicity. Moreover, MC induced the release of TGF-β1, and increased expression of PAR-2, ERK1/2 and Akt activation. Accordingly, TGF-β1, tryptase and other pro-inflammatory and immunosuppressive cytokines increased in the unresponsive patients. In conclusion, MC play a pivotal role in the resistance to GEM/NAB. A correlation between high level of circulating pro-inflammatory/ immunosuppressive cytokines and unresponsiveness was found in PDAC patients.

3 Article Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. 2019

Beleù, Alessandro / Calabrese, Angela / Rizzo, Giulio / Capelli, Paola / Bellini, Nicolò / Caloggero, Simona / Calbi, Roberto / Tinazzi Martini, Paolo / De Robertis, Riccardo / Carbognin, Giovanni / Marchegiani, Giovanni / Scarpa, Aldo / Salvia, Roberto / Bassi, Claudio / D'Onofrio, Mirko. ·Department of Radiology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. ale.beleu@gmail.com. · Department of Radiology, Istituto Oncologico Giovanni Paolo II, 70124 Bari, Italy. acalabrese22@gmail.com. · Department of Radiology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. giulioriz11@gmail.com. · Department of Pathology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. paolacapelli@hotmail.com. · Department of Radiology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. bellini.nico@live.it. · Department of Radiology, G. Martino Hospital, University of Messina, 98125 Messina, Italy. simona.caloggero@hotmail.it. · Department of Radiology, Ospedale Generale Regionale "F. Miulli", 70021 Acquaviva della Fonti, Italy. calbi.roberto@gmail.com. · Department of Radiology, Ospedale P. Pederzoli, 37019 Peschiera del Garda, Italy. paolo.tinazzimartini@univr.it. · Department of Radiology, Ospedale Civile Maggiore Borgo Trento, Azienda Ospedaliera Universitaria Integrata, 37134 Verona, Italy. riccardo.derobertislombardi@univr.it. · Department of Radiology, Ospedale "Sacro Cuore, Don Calabria", 37024 Negrar, Italy. giovanni.carbogni@univr.it. · Department of Surgery, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. giovanni.marchegiani@aovr.veneto.it. · Department of Pathology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. aldo.scarpa@univr.it. · Department of Surgery, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. roberto.salvia@univr.it. · Department of Surgery, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. claudio.bassi@univr.it. · Department of Radiology, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. mirko.donofrio@univr.it. ·Cancers (Basel) · Pubmed #30823544.

ABSTRACT: INTRODUCTION: Evaluation of pancreatic ductal adenocarcinoma (PDAC) after chemoradiotherapy downstaging is challenging due to computed tomography (CT) overestimation of tumor extension and residual vascular involvement, limiting access to surgery to some patients with potentially resectable tumors. With this study, we wanted to assess which radiological findings are most reliable at pre-operative imaging in the evaluation of PDAC after chemoradiotherapy in order to achieve complete resection. METHODS: We retrospectively enrolled 71 patients with locally advanced and borderline resectable PDAC who underwent neoadjuvant chemoradiotherapy. Pre-operative CT or magnetic resonance (MR) have been evaluated by three radiologists to assess major qualitative and quantitative parameters of lesions. Accuracy, sensitivity, and specificity compared to anatomopathological results were evaluated for each parameter. Cohen's K-coefficient has been calculated to evaluate the inter-observer agreement (IOA). Both single and consensus lecture have been tested. Different dimensional cut-offs were tested to categorize tumors according to their major axis and to compare with anatomopathological diameter, tumor persistence, and margin infiltration. RESULTS: A 25 mm cut-off was 67% sensitive, 90% specific, and 77% accurate in assessing real tumor dimension. 25 mm cut-off reported a 64% sensitivity, 78% specificity, and 69% accuracy in assessing R0 resection. Each 5 mm increment of major axis dimension there is an odds ratio (OR) 1.79 (95% CI 1.13⁻2.80, CONCLUSION: Imaging methods tend to underestimate PDAC resectability after neoadjuvant-CRT. IOA is poor to fair in evaluating most of the qualitative parameters of downstaged pancreatic adenocarcinoma. Surgery should be considered for downstaged borderline resectable PDACs, independently from perivascular cuff presence, especially for tumors smaller than 25 mm.

4 Article Angiogenesis in adenosquamous cancer of pancreas. 2017

Silvestris, Nicola / Danza, Katia / Longo, Vito / Brunetti, Oronzo / Fucci, Livia / Argentiero, Antonella / Calabrese, Angela / Cataldo, Ivana / Tamma, Roberto / Ribatti, Domenico / Tommasi, Stefania. ·Medical Oncology Unit and Scientific Directorate, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. · Molecular Genetics Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. · Medical Oncology Unit, Hospital "S. G. Moscati" of Taranto, 74010, Taranto, Italy. · Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. · Histopatology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. · Radiology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. · ARC-Net Research Centre, University and Hospital Trust of Verona, 37134, Verona, Italy. · Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, 70124, Bari, Italy. · IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy. ·Oncotarget · Pubmed #29221165.

ABSTRACT: Adenosquamous carcinoma of the pancreas (ASCP) is an uncommon variant of exocrine pancreatic malignancies, characterized by a histological admixture of adenomatous and squamous cell elements. This cancer is characterized by a poorly differentiated histology and a poorer clinical outcome compared to pancreatic ductal adenocarcinoma (PDAC). Unlike PDAC, that is characterized by a low microvascular density (MVD) and collapsed vasculature, no data are available about angiogenesis in ASPC. Immunohistochemical evaluation of MVD and trypatse-positive mast cells (MCs) were performed on a single case of ASCP compared to PDAC. Moreover, the levels of angiopoietin-1 and -2 (Ang-1, Ang-2), receptor tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (Tie-2), vascular endothelial growth factor A (VEGFA), hypoxia-inducible factor 1 alpha (HIF1A), miR-21-5p, miR-181a-5p, miR-122-5p, and miR-27a-3p were evaluated by real-time PCR. Higher number of tryptase-positive MCs and MVD are observed in the ASCP case compared to PDAC one. Lower levels of miR-122-5p and higher expression of VEGFA, HIF1A and Ang-2 genes were observed in ASCP. Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma. Our data demonstrate an important angiogenic activity in ASCP with a putative role of miR-21-5p, miR-181a-5p, miR-122-5p and miR-27a-3p in the regulation of this process.